Clinical trial
The Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin (PONTiAK) Trial: A Phase 2B Vanguard Design, Randomized, Double-Blind, Placebo-Controlled Study
NCT06886464 is registered in ClinicalTrials.gov with Matthew James as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin (PONTiAK) Trial: A Phase 2B Vanguard Design, Randomized, Double-Blind, Placebo-Controlled Study
- Lead sponsor
- Matthew James
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 16, 2025
- Completion date
- December 31, 2029
- Enrollment
- 698 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.